Epidermolysis bullosa acquisita is a rare chronic autoimmune blistering disease.
Epidemiology
Incidence – 0.25 cases per million
Age of onset – all ages, peak onset age 40-50
Gender – M:F equal distribution
Pathology and Immunopathology
Subdermal blister formation
Linear basement membrane zone deposition of IgG in perilesional tissue by direct immunofluorescence
Dermal localization of serum basement membrane zone antibodies on split skin by indirect immunofluorescence
Clinical Presentation
Lesions of skin on areas of trauma and/or oral mucosa
Tense blisters with serous or hemorrhagic fluid
Diagnosis
Laboratory testing
Epithelial skin antibodies
IgG basement membrane zone antibodies
Differential Diagnosis
Bullous pemphigoid
Linear IgA disease
Porphyria cutanea tarda
Bullous drug reaction
Contact dermatitis
Disease Monitoring
IgG basement zone antibodies
IgG BP180 and BP230 antibody levels are NOT elevated as in pemphigoid; rather, the target antigen is collagen VII, accounting for the dermal staining pattern on human split skin substrate
Perilesional biopsy sent for cutaneous direct immunofluorescence is also recommended
Epithelial Basement Membrane Zone IgG Antibodies 0092056
Method: Indirect Immunofluorescence (IFA)
Establish diagnosis of pemphigoid or epidermolysis bullosa acquisita in patients suspected of having or known to have any type of pemphigoid or epidermolysis bullosa acquisita
Distinguish these diseases from each other and other immunobullous disease, such as pemphigus and dermatitis herpetiformis
Clinical correlation necessary since incidence of false-positives, although rare, increases with age
Linear IgA disease may be missed
Perilesional skin biopsy for cutaneous direct immunofluorescence is helpful in diagnosis (>90% of epidermolysis bullosa acquisita cases show IgG basement membrane zone staining)
General References
Hallel-Halevy D, Nadelman C, Chen M, Woodley DT.Epidermolysis bullosa acquisita: update and review.Clin Dermatol. 2001;19(6):712-718. (Link to PubMed)
Harman KE.New laboratory techniques for the assessment of acquired immunobullous disorders.Clin Exp Dermatol. 2002;27(1):40-46. (Link to PubMed)
Luke MC, Darling TN, Hsu R, Summers RM, Smith JA, Solomon BI, Thomas GR, Yancey KB.Mucosal morbidity in patients with epidermolysis bullosa acquisita.Arch Dermatol. 1999;135(8):954-959. (Link to PubMed)
Mutasim DF, Adams BB.Immunofluorescence in dermatology.J Am Acad Dermatol. 2001;45(6):803-822. (Link to PubMed)
Reviewed by
Leiferman, Kristin M., M.D. Co-Director, Immunodermatology Laboratory at ARUP Laboratories; Professor, Dermatology, University of Utah
Zone, John J., M.D. Co-Director, Immunodermatology Laboratory at ARUP Laboratories; Professor and Chairman, Dermatology, University of Utah
Comprehensive Review: September 2007
Last Update: September 2007